Artificial Intelligence powered brain imaging leader icometrix raises $18 million through a partnership with Forestay Capital. Other partners are Optum Ventures and Capricorn Venture Partners — the latter is also an existing investor.
CE-marked and FDA-approved icobrain, icometrix’s flagship product, extracts meaningful insights from brain scans of patients suffering from neurological disorders.
Few of the common disorders where icobrain is positively assisting doctors are –
- Multiple Sclerosis
- Alzheimer’s disease
- Traumatic brain injury
“With icobrain, medical images can be read faster, more consistently and in a more personalized fashion by quantifying the volume of brain structures and abnormalities,” said Wim Van Hecke, CEO of icometrix. “One in three people will suffer from a brain disorder, often due to a chronic disease, leading to an immense burden for patients, friends, families, caregivers, and society. Brain scans play a central role in patient diagnosis and monitoring, creating a huge need for objective and patient-specific evaluation of MRI and CT brain scan images with tools like icobrain.”
“Forestay is delighted to partner with icometrix‘s management and to help drive forward its growing success story. This technology transforms the way we diagnose, monitor, and treat people with brain disorders and we can see its immense potential to improve neurological diagnostics, making a complex process quicker and more effective for each individual patient. Our own investor, the Waypoint Capital group, has a deep heritage in the health care sector and also owns Affidea, the largest imaging center network in Europe, which has partnered with icometrix to develop the standardization protocols for its large-scale deployment across Europe. This gives us great confidence in its future value potential,” said Frederic Wohlwend, Managing Partner of Forestay Capital.
“We strongly believe in the power of data to help diagnose, monitor and treat neurological disorders,” said Heather Roxborough, Partner at Optum Ventures. “By putting icometrix‘s innovative AI brain imaging solutions in the hands of clinicians and radiologists worldwide, we can help improve the lives of millions of people with brain disorders.”
The company’s AI-powered solution, icobrain, is already being leveraged by more than a 100 medical facilities and imaging centers, worldwide. Four out of Five leading pharmaceutical corporations use the product for extensive clinical studies.